It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pathological variants of human mitochondrial DNA (mtDNA) typically co-exist with wild-type molecules, but the factors driving the selection of each are not understood. Because mitochondrial fitness does not favour the propagation of functional mtDNAs in disease states, we sought to create conditions where it would be advantageous. Glucose and glutamine consumption are increased in mtDNA dysfunction, and so we targeted the use of both in cells carrying the pathogenic m.3243A>G variant with 2-Deoxy-D-glucose (2DG), or the related 5-thioglucose. Here, we show that both compounds selected wild-type over mutant mtDNA, restoring mtDNA expression and respiration. Mechanistically, 2DG selectively inhibits the replication of mutant mtDNA; and glutamine is the key target metabolite, as its withdrawal, too, suppresses mtDNA synthesis in mutant cells. Additionally, by restricting glucose utilization, 2DG supports functional mtDNAs, as glucose-fuelled respiration is critical for mtDNA replication in control cells, when glucose and glutamine are scarce. Hence, we demonstrate that mitochondrial fitness dictates metabolite preference for mtDNA replication; consequently, interventions that restrict metabolite availability can suppress pathological mtDNAs, by coupling mitochondrial fitness and replication.
It has been a longstanding goal to promote the propagation of functional mitochondrial DNAs at the expense of pathological molecules in cells where the two species coexist. Here, the authors show that restricting the availability of glucose and glutamine can achieve this outcome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Royal Free Campus, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK (GRID:grid.426108.9) (ISNI:0000 0004 0417 012X)
2 Biodonostia Health Research Institute, San Sebastián, Spain (GRID:grid.432380.e)
3 Biodonostia Health Research Institute, San Sebastián, Spain (GRID:grid.432380.e); Universidad de País Vasco, Department of Pediatrics, Medicine and Nursing Faculty, Bilbao, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098)
4 University of Padova, Department of Neurosciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
5 University of Bergen, Faculty of Mathematics and Natural Sciences, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443)
6 UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Department of Neuromuscular Diseases, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631)
7 Faculty of Medical Sciences Newcastle University, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
8 Royal Free Campus, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK (GRID:grid.426108.9) (ISNI:0000 0004 0417 012X); Biodonostia Health Research Institute, San Sebastián, Spain (GRID:grid.432380.e); Basque Foundation for Science, IKERBASQUE, Bilbao, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314); CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases, Ministry of Economy and Competitiveness, Institute Carlos III), Madrid, Spain (GRID:grid.418264.d) (ISNI:0000 0004 1762 4012); Universidad de País Vasco, Barrio Sarriena s/n, Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098)